China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market Growing Trade Among Emerging Economies Opening New Opportunities (2023-2028)

Report Overview

China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics market size stood at around USD 0.0466 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Neuromyelitis optica spectrum disorder (NMOSD) is a severe inflammatory disease of the central nervous system (CNS) with preferential involvement of the optic nerve and spinal cord. NMOSD has an estimated annual incidence of 40,000 in China, with 60% of patients relapse in one year. The peak incidence was among those aged 4565 years, mainly in females, the female to male ratio is 4.71:1. From 2015 to 2019, in China the prevalence of NMOSD in adults increased from 37200 to 39200. Approximately 80% of the NMOSD patient population are AQP4+ cases, in which a persons own immune system attacks the astrocytes of the optic nerve, spinal cord and brainstem.

Market Drivers

China is a growing market for neuromyelitis optica spectrum disorder (NMOSD) disease due to increase in Chinas prevalence rate (From 2015 to 2019, the prevalence of NMOSD in adults increased from 37200 to 3920) and improvement in healthcare facilities. In addition to these, the emergence of biologics and adoption of novel therapeutics are further pushing the market growth.Other factors that contribute to the growth of the market are increase in population and government initiatives.

Less trained expertise or technically skilled professionals coupled with high treatment cost significantly hinder the growth of neuromyelitis optica spectrum disorder (NMOSD) therapeutics market.

Get Exclusive Free Sample Report @ https://www.prudentmarkets.com/sample-request/139793/

Major Players

Some of the key players in China neuromyelitis optica spectrum disorder (NMOSD) therapeutics market are Alexion Pharmaceuticals Inc; Viela Bio, Inc; F. Hoffmann-La Roche Ltd; Hansoh Pharma; Harbour Biomed (HBM) Holdings Limited; Accendatech Co. Ltd; Bio-Thera Solutions Ltd; RemeGen Biosciences.

Key players are adopting various strategies such as licensing agreement, strategic collaboration and partnerships. For instance, Viela Bio Enters Strategic Collaboration with Hansoh Pharma to Develop and Commercialize Inebilizumab in China for neuromyelitis optica spectrum disorder (NMOSD).

In April 2020, China's Centre for Drug Evaluation (CDE) accepted a licensing application for ENSPRYNG (Satralizuma) for treatment of neuromyelitis optica spectrum disorder (NMOSD).

The report delivers the challenges in front of the China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market 2023 that allows a better understanding of the market providing a helpful comprehensive evaluation and clear-cut dynamics associated with this market. The analyst has studied the current market scenario while concentrating on the new business objectives with the lucrative opportunities that are available. This report includes changes in customer requirements, customer preferences, and the vendor landscape in the industry with key factors that are expected to influence the overall dynamics of the China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeuticss Market including the current trends, growth opportunities, restraints, and market drivers.

To Know More About COVID-19 Impact On China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market @ https://www.prudentmarkets.com/sample-request/139793/

Market Segmentation

By Drug Type:

On the basis of drug type, the China neuromyelitis optica spectrum disorder (NMOSD) therapeutics market can be segmented into C5 Protein Inhibitor, monoclonal antibodies, corticosteroids, immunosuppressive agents. For acute attacks, the standard treatment is high-dose intravenous corticosteroids, typically Methylprednisolone. Plasma exchange may be effective in patients who experience acute severe attacks that do not respond to intravenous corticosteroids.

By Route of Administration:

On the basis of route of administration, the China neuromyelitis optica spectrum disorder (NMOSD) therapeutics market can be segmented into oral and parenteral. Oral route of administration is dominating the market during the forecast period (2019-2028) due to its convenience and pain free administration. Parenteral route of administration is preferred in case of acute attacks.

By Distribution Channels:

On the basis of distribution channels, the China neuromyelitis optica spectrum disorder (NMOSD) therapeutics market can be segmented into retail, online and hospital pharmacies. During the forecast period (2019-2028) hospital pharmacies are the key distribution channels as they have a large patient base compared to other healthcare facilities and they also conduct various clinical trials. In addition to these the other factors that contribute to growth of the hospital pharmacies segment is increasing incidence (0.287/100,000 persons/year) of neuromyelitis optica spectrum disorder (NMOSD) and rising number of admissions of patients with the disease.

Major Players

Some of the key players in China neuromyelitis optica spectrum disorder (NMOSD) therapeutics market are Alexion Pharmaceuticals Inc; Viela Bio, Inc; F. Hoffmann-La Roche Ltd; Hansoh Pharma; Harbour Biomed (HBM) Holdings Limited; Accendatech Co. Ltd; Bio-Thera Solutions Ltd; RemeGen Biosciences.

Key players are adopting various strategies such as licensing agreement, strategic collaboration and partnerships. For instance, Viela Bio Enters Strategic Collaboration with Hansoh Pharma to Develop and Commercialize Inebilizumab in China for neuromyelitis optica spectrum disorder (NMOSD).

In April 2020, China's Centre for Drug Evaluation (CDE) accepted a licensing application for ENSPRYNG (Satralizuma) for treatment of neuromyelitis optica spectrum disorder (NMOSD).

The China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market report is an easy-to-understand document giving section-wise details about the global market. Starting with the brief outline of the overall market, it will put forth the all-inclusive evaluated market statistics and different parameters for the forecast period. The report covers numerous aspects of the China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics market divided into product kind, application, and end-use, offering the report to assist the customers in improving their ability to make precise decisions related to the business under the China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market.

International Market Players will use the correct market facts and figures and applied math studies provided within the report back to perceive this and future growth of the worldwide Electrophoretic China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics market. Each section of the research study is specially prepared to explore key aspects of the global China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market. Buyers of the report will have access to accurate PESTLE, SWOT, and other types of analysis on the global China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries.

This post-pandemic business planning research will aid clients to:
• Adjust their strategic planning to move ahead once business stability kicks in.
• Build resilience by making effective resource and investment choices for individual business units, products, and service lines.
• Conceptualize scenario-based planning to mitigate future crisis situations.

Instant Buy This Report and Get Up To 40% Discount [Use Corporate Email ID]: https://www.prudentmarkets.com/discount-request/139793/

Get full copy of 225+ pages research report (Inclusion of updated research on COVID-19) on United States Region at $1500 and, Europe region at $2000. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Our qualified team of researchers, analysts, and consultants use in-depth qualitative research, quantitative research, and the latest recognized research techniques to offer an unrivaled level of detail and value to your research activities. Our market and competitive intelligence can be utilized by teams across multiple departments, including sales and business development, marketing, to:

• Access the latest information on potential competitors and customers through a comprehensive database
• Analyse the business strategies and collaborations of multiple companies within a specific market
• Identify new markets and regions for future expansion
• Compare financial trends between competitor companies
• Get to know about mergers and acquisitions
• Explore the strengths and weaknesses of companies cross-industry
• Improve your business modeling

Strategic Points Covered in Table of Content of Global China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics
Chapter 4: Presenting the China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the China Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

(If you have any special requirements, please let us know and we will offer you the report as you want.)

Inquire Before Purchasing The Complete Report To Grow Your Business: https://www.prudentmarkets.com/enquiry-request/139793/

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.